Lataa...
Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer
Inhibition of tumor angiogenesis has emerged as an important therapeutic component in the management of metastatic colorectal cancer. Three anti-angiogenic agents are currently approved in this clinical setting: bevacizumab, ziv-aflibercept, and regorafenib. Bevacizumab, a monoclonal antibody that t...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Pioneer Bioscience Publishing Company
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3712300/ https://ncbi.nlm.nih.gov/pubmed/23997941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2013.030 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|